Flatiron Health, a trailblazer in healthtech and real-world oncology research, has announced the launch of six groundbreaking hematology Panoramic datasets. This milestone represents a pivotal advancement in the company’s real-world evidence (RWE) capabilities, leveraging cutting-edge AI and large language models to redefine how blood cancers are studied and treated.
Flatiron’s Panoramic datasets encompass over 505,000 patient records across five B-cell lymphoma subtypes and multiple myeloma, forming part of a vast repository of more than five million cancer patient records. With 1.5 billion data points reflecting real-world clinical practices across diverse care settings, these datasets aim to transform hematologic malignancy research by providing unparalleled insights into patient experiences.
This latest release marks a six-fold increase in cohort size compared to Flatiron’s previous hematology collections. The datasets include rich longitudinal data, such as measurable residual disease (MRD) testing and CAR-T therapy utilization—key metrics in modern hematology. These enhancements enable researchers to analyze treatment patterns, adherence, and outcomes with unprecedented precision, paving the way for personalized therapies and more inclusive clinical trial designs.
Nathan Hubbard, CEO of Flatiron Health, described the Panoramic datasets as the culmination of a decade-long effort to build a global oncology evidence infrastructure. By combining advanced AI and machine learning with rigorous scientific validation, Flatiron is enabling more precise, individualized care for patients with blood cancers. The datasets also enhance interoperability, allowing researchers to conduct streamlined analyses across related lymphoma types and track disease transformations over time.
Flatiron’s hematology program supports in-depth investigations into complex patient subgroups, such as high-grade B-cell lymphomas with MYC, BCL2, and BCL6 rearrangements, as well as high-risk multiple myeloma cases with challenging cytogenetics. The datasets provide a comprehensive view of real-world effectiveness, molecular responses, and adverse events, complementing traditional clinical trial data. By integrating insights from inpatient and outpatient care, infusion and oral regimens, and cellular therapies, the Panoramic datasets offer a holistic view of the patient journey that was previously fragmented.
With over 250 publications and 275 research presentations slated for global conferences in 2025, Flatiron continues to set the standard for digital oncology evidence. The company’s participation in ISPOR Europe and ASH 2025 highlights its commitment to responsibly applying AI and RWE to expand access for rare disease populations, close data gaps, and drive the next wave of hematology innovation.
Flatiron’s Panoramic datasets represent a transformative leap forward, empowering researchers and clinicians to better understand and treat blood cancers while advancing the broader field of oncology.
About Flatiron Health
FLATIRON HEALTH® is a healthtech company dedicated to improving cancer treatment and advancing research. As the pioneer in real-world evidence for oncology, they provide technology and services to support patient care and make every person’s story count. Flatiron Health partners with hundreds of cancer centers, 20+ top global developers of oncology therapeutics, and researchers and regulators around the world.
Founded in 2012, Flatiron became an independent affiliate of the Roche Group in 2018. In years since, they have expanded their commitment to advance research and treatment for patients around the globe. Flatiron International subsidiaries in Japan, Germanyand the United Kingdom will partner with hospitals and health networks in collaborations tailored to each market’s needs and legal, regulatory and compliance requirements.
The post Flatiron Unveils 6 AI-Driven Hematology Datasets to Revolutionize Blood Cancer Research appeared first on PRISM MarketView.
